During the past decade, UAB CCC Clinical Studies Unit conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "UAB CCC Clinical Studies Unit" are "Lymphoma, B-Cell" (1 trials) and "Non Small Cell Lung Carcinoma" (1 trials). Many other conditions were trialed in "UAB CCC Clinical Studies Unit" in a lesser frequency.

Most popular intervention types in "UAB CCC Clinical Studies Unit" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Inotuzumab ozogamicin [CMC-544]" (1 trials), "TLK286 (Telcyta) HCl for Injection" (1 trials) and "gefitinib (Iressa)" (1 trials). Other intervention names were less common.

The vast majority of trials in "UAB CCC Clinical Studies Unit" are 2 trials for "All" genders.

Currently, there are NaN active trials in "UAB CCC Clinical Studies Unit". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in UAB CCC Clinical Studies Unit, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in UAB CCC Clinical Studies Unit, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".